Skip to main content
Erschienen in: Strahlentherapie und Onkologie 4/2015

01.04.2015 | Literatur kommentiert

Akzelerierte versus konventionelle Fraktionierung bei der kombinierten Radiochemotherapie von Kopf-Hals-Tumoren

verfasst von: PD Dr. med. Martina Becker-Schiebe, Prof. Dr. med. Hans Christiansen

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Auszug

Ziel der StudiePrüfung der Wirksamkeit und Toxizität eines akzelerierten Bestrahlungsschemas mit integriertem Boost (AFX-C) gegenüber einer konventionellen Fraktionierung (SFX) im Rahmen der Radiochemotherapie (RCT) lokal fortgeschrittener Kopf-Hals-Tumoren mit Cisplatin (LA-HNC). …
Literatur
1.
2.
Zurück zum Zitat Baujat B, Bourhis J, Blanchard P et al (2010) Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev 12:CD002026PubMed Baujat B, Bourhis J, Blanchard P et al (2010) Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev 12:CD002026PubMed
3.
Zurück zum Zitat Becker-Schiebe M, Hoffmann W, Pinkert U et al (2008) Prognostic impact of p53 mutations and loss of heterozygosity at 9p21 and 11p15 in head and neck cancer. Trends Cancer Res 4:19–24 Becker-Schiebe M, Hoffmann W, Pinkert U et al (2008) Prognostic impact of p53 mutations and loss of heterozygosity at 9p21 and 11p15 in head and neck cancer. Trends Cancer Res 4:19–24
4.
Zurück zum Zitat Beitler JJ, Zhang Q, Fu KK et al (2014) Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 89(1):13–20CrossRefPubMed Beitler JJ, Zhang Q, Fu KK et al (2014) Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 89(1):13–20CrossRefPubMed
5.
Zurück zum Zitat Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854CrossRefPubMed Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854CrossRefPubMed
6.
Zurück zum Zitat Bourhis J, Sire C, Graff P et al (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 13:145–153CrossRefPubMed Bourhis J, Sire C, Graff P et al (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 13:145–153CrossRefPubMed
7.
Zurück zum Zitat Budach W, Hehr T, Budach V et al (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28CrossRefPubMedCentralPubMed Budach W, Hehr T, Budach V et al (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16CrossRefPubMed Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16CrossRefPubMed
9.
Zurück zum Zitat Pignon JP, le Maître A, Maillard E et al (2009) Metaanalysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMed Pignon JP, le Maître A, Maillard E et al (2009) Metaanalysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMed
10.
Zurück zum Zitat Rischin D, Young R, Fisher R et al (2010) Prognostic significance of p16 INK4A and HPF in patients with oropharyngeal cancer treated on TROG 0202 Phase III Trial. J Clin Oncol 28:4142–4148CrossRefPubMedCentralPubMed Rischin D, Young R, Fisher R et al (2010) Prognostic significance of p16 INK4A and HPF in patients with oropharyngeal cancer treated on TROG 0202 Phase III Trial. J Clin Oncol 28:4142–4148CrossRefPubMedCentralPubMed
Metadaten
Titel
Akzelerierte versus konventionelle Fraktionierung bei der kombinierten Radiochemotherapie von Kopf-Hals-Tumoren
verfasst von
PD Dr. med. Martina Becker-Schiebe
Prof. Dr. med. Hans Christiansen
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 4/2015
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0819-1

Weitere Artikel der Ausgabe 4/2015

Strahlentherapie und Onkologie 4/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.